Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
12.34
+0.51 (4.31%)
Dec 20, 2024, 4:00 PM EST - Market closed
Mineralys Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -153.25 | -71.9 | -29.8 | -19.41 | -3.43 |
| Loss (Gain) From Sale of Investments | -10.13 | -6.87 | -0.65 | - | - |
| Stock-Based Compensation | 9.66 | 5.06 | 0.46 | 0.08 | 0 |
| Other Operating Activities | - | - | - | 0.68 | 0.48 |
| Change in Accounts Payable | 17.78 | 2.42 | 3.01 | 4.47 | 0.54 |
| Change in Other Net Operating Assets | 7.47 | -9.89 | -2.24 | -0.39 | -0.06 |
| Operating Cash Flow | -128.45 | -81.17 | -29.22 | -14.56 | -2.46 |
| Investment in Securities | 23.4 | -160.47 | -21.76 | - | - |
| Investing Cash Flow | 23.3 | -160.47 | -21.76 | - | - |
| Short-Term Debt Issued | - | - | - | - | 3.85 |
| Total Debt Issued | - | - | - | - | 3.85 |
| Net Debt Issued (Repaid) | - | - | - | - | 3.85 |
| Issuance of Common Stock | 116.51 | 203.25 | - | - | - |
| Other Financing Activities | -0.39 | - | -1.63 | - | -0.02 |
| Financing Cash Flow | 116.13 | 203.25 | 128.02 | 23.81 | 3.83 |
| Net Cash Flow | 10.97 | -38.4 | 77.04 | 9.25 | 1.37 |
| Free Cash Flow | -128.55 | -81.17 | -29.22 | -14.56 | -2.46 |
| Free Cash Flow Per Share | -2.79 | -2.24 | -5.65 | -2.92 | -0.53 |
| Levered Free Cash Flow | -70.36 | -55.27 | -18.4 | -7.62 | - |
| Unlevered Free Cash Flow | -70.36 | -55.27 | -18.4 | -7.61 | - |
| Change in Net Working Capital | -25.26 | 7.42 | -0.82 | -4.02 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.